BREA SWIHART: Open Payments
NPI 1659669042 · AUGUSTA, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,400 in 23 payments from 10 companies in 2025. Trend: 2023 $1,350 · 2024 $610 · 2025 $1,400
Consulting: $800Food & beverage: $588Education: $12
| Company | Payments | Amount |
|---|---|---|
| Celltrion USA Inc. | 1 | $800 |
| Madrigal Pharmaceuticals | 6 | $250 |
| Gilead Sciences, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| ABBVIE INC. | 3 | $54 |
| Lilly USA, LLC | 2 | $40 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Novo Nordisk Inc | 1 | $14 |
Products named: ZYMFENTRA, REZDIFFRA, ENTYVIO, OMVOH, RINVOQ, ZENPEP, IQIRVO, XIFAXAN.
Industry payments across ME — which companies pay providers there.
